News

Change of Adviser

11 February 2008

Lipoxen plc

Change of Adviser

London, UK, 11 February, 2008 - Lipoxen PLC (AIM: LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, today announces the appointment of Landsbanki Securities (UK) Limited as Nominated Adviser and Broker to the company with immediate effect.

Enquiries:
Lipoxen plc
M. Scott Maguire, Chief Executive Officer
Colin Hill, Finance Director
+44 (0)20 7691 3583
Landsbanki Securities (UK) Limited
Shaun Dobson
Claes Spång
+44 (0)20 7426 9000
Citigate Dewe Rogerson
David Dible
Emma Palmer
+44 (0)20 7638 9571